SYH9056

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Phase 3 active Small molecule

SYH9056 is a small-molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival.

At a glance

Generic name	SYH9056
Sponsor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

While detailed mechanism information is limited in public sources, SYH9056 is being developed by CSPC ZhongQi Pharmaceutical as an investigational oncology agent in Phase 3 trials. The drug appears to target intracellular signaling pathways critical for tumor growth, though the precise molecular target requires further confirmation from clinical trial data.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SYH9056 CI brief — competitive landscape report
SYH9056 updates RSS · CI watch RSS
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. portfolio CI